Compatibility of Cholecalciferol, Haloperidol, Imipramine Hydrochloride, Levodopa/carbidopa, Lorazepam, Minocycline Hydrochloride, Tacrolimus Monohydrate, Terbinafine, Tramadol Hydrochloride and Valsartan in SyrSpend SF PH4 Oral Suspensions
Overview
Affiliations
A challenge with compounding oral liquid formulations is the limited availability of data to support the physical, chemical and microbiological stability of the formulation. This poses a patient safety concern and a risk for medication errors. The objective of this study was to evaluate the compatibility of the following active pharmaceutical ingredients (APIs) in 10 oral suspensions, using SyrSpend SF PH4 (liquid) as the suspending vehicle: cholecalciferol 50,000 IU/mL, haloperidol 0.5 mg/mL, imipramine hydrochloride 5.0 mg/mL, levodopa/carbidopa 5.0/1.25 mg/mL, lorazepam 1.0 mg/mL, minocycline hydrochloride 10.0 mg/mL, tacrolimus monohydrate 1.0 mg/mL, terbinafine 25.0 mg/mL, tramadol hydrochloride 10.0 mg/mL and valsartan 4.0 mg/mL. The suspensions were stored both refrigerated (2 - 8 degrees C) and at controlled room temperature (20 - 25 degrees C). This is the first stability study for these APIs in SyrSpend SF PH4 (liquid). Further, the stability of haloperidol,ilmipramine hydrochloride, minocycline, and valsartan in oral suspension has not been previously reported in the literature. Compatibility was assessed by measuring percent recovery at varying time points throughout a 90 days period. Quantification of the APIs was performed by high performance liquid chromatography (HPLC-UV). Given the percentage of recovery of the APIs within the suspensions, the beyond-use date of the final preparations was found to be at least 90 days for most suspensions both refrigerated and at room temperature. Exceptions were: Minocycline hydrochloride at both storage temperatures (60 days), levodopa/carbidopa at room temperature (30 days), and lorazepam at room temperature (60 days). This suggests that compounded suspensions of APIs from different pharmacological classes in SyrSpend SF PH4 (liquid) are stable.
Mansourian M, Dijkers E, Silva C, Polonini H Pharmaceutics. 2023; 15(10).
PMID: 37896148 PMC: 10609746. DOI: 10.3390/pharmaceutics15102388.
Limited Influence of Excipients in Extemporaneous Compounded Suspensions.
Dijkers E, Nanhekhan V, Thorissen A, Marro D, Uriel M Hosp Pharm. 2017; 52(6):428-432.
PMID: 29276267 PMC: 5735698. DOI: 10.1177/0018578717717393.
Stability of gabapentin in extemporaneously compounded oral suspensions.
Friciu M, Roullin V, Leclair G PLoS One. 2017; 12(4):e0175208.
PMID: 28414771 PMC: 5393583. DOI: 10.1371/journal.pone.0175208.
Stability of Levodopa/Carbidopa Rectal Suspensions.
Donnelly R Hosp Pharm. 2017; 51(11):915-921.
PMID: 28057951 PMC: 5199224. DOI: 10.1310/hpj5111-915.
Stability of Diazoxide in Extemporaneously Compounded Oral Suspensions.
Friciu M, Zaraa S, Roullin V, Leclair G PLoS One. 2016; 11(10):e0164577.
PMID: 27727306 PMC: 5058506. DOI: 10.1371/journal.pone.0164577.